Aclaris Therapeutics, Inc. (ACRS) News
Filter ACRS News Items
ACRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ACRS News From Around the Web
Below are the latest news stories about Aclaris Therapeutics Inc that investors may wish to consider to help them evaluate ACRS as an investment opportunity.
Aclaris Therapeutics GAAP EPS of -$0.37 misses by $0.01, revenue of $1.5M misses by $0.3MAclaris Therapeutics press release (ACRS): Q4 GAAP EPS of -$0.37 misses by $0.01.Revenue of $1.5M (-5.1% Y/Y) misses by $0.3M. |
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue EstimatesAclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateWAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update. “2021 was a tremendous year for the progression of our drug development pipeline, and I’m very proud of what our team has accomplished,” said Dr. Neal Walker, President & CEO |
Aclaris Therapeutics Q4 2021 Earnings Preview (NASDAQ:ACRS)Aclaris Therapeutics (NASDAQ:ACRS) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.36 and the consensus |
Those who invested in Aclaris Therapeutics (NASDAQ:ACRS) three years ago are up 97%By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at... |
Earnings Preview: Aclaris Therapeutics (ACRS) Q4 Earnings Expected to DeclineAclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
There Is A Lot Of Upside Potential For Aclaris Therapeutics Inc.(NASDAQ: ACRS)Aclaris Therapeutics Inc. (NASDAQ:ACRS) price on Friday, February 11, rose 0.87% above its previous days close as an upside momentum from buyers pushed the stocks value to $12.71. A look at the stocks price movement, the close in the last trading session was $12.60, moving within a range at $12.43 and $13.10. The beta value There Is A Lot Of Upside Potential For Aclaris Therapeutics Inc.(NASDAQ: ACRS) Read More » |
Did Hedge Funds Catch A Break With Aclaris Therapeutics, Inc. (ACRS)?The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. |
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare ConferenceWAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET. Management will be available February 16th throughout the day for vir |
Aclaris Therapeutics Expands Leadership TeamAppoints James Loerop as Chief Business Officer WAYNE, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of James Loerop as Chief Business Officer, effective January 31, 2022. “We are excited to welcome Jim to Aclaris,” said Dr. Neal Walker, President and CEO of Aclaris. “His experience as a business development l |